HTT and Huntington disease: AAV-mediated delivery of Cas13d–CAGEX to the striatum of premanifest zQ175/+ HD mice resulted in allele-selective suppression of mutant HTT mRNA and protein aggregates while maintaining normal HTT mRNA and protein levels, significantly improved motor function and attenuated striatal atrophy.